Ticker > Company >

Lincoln Pharma share price

Lincoln Pharmaceuticals Ltd.

NSE: LINCOLN BSE: 531633 SECTOR: Pharmaceuticals & Drugs  85.06 K   332   48

556.05
-2.65 (-0.47%)
NSE: Today, 10:14 AM

Price Summary

Today's High

₹ 560.9

Today's Low

₹ 556

52 Week High

₹ 979.5

52 Week Low

₹ 499

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1113.75 Cr.

Enterprise Value

1101.43 Cr.

No. of Shares

2 Cr.

P/E

12.9

P/B

1.59

Face Value

₹ 10

Div. Yield

0.32 %

Book Value (TTM)

₹  349.15

CASH

13.39 Cr.

DEBT

1.07 Cr.

Promoter Holding

49.78 %

EPS (TTM)

₹  43.11

Sales Growth

13.76%

ROE

17.04 %

ROCE

22.53%

Profit Growth

27.99 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year13.76%
3 Year11.14%
5 Year10.46%

Profit Growth

1 Year27.99%
3 Year14.44%
5 Year14.88%

ROE%

1 Year17.04%
3 Year16.66%
5 Year17.2%

ROCE %

1 Year22.53%
3 Year22.88%
5 Year23.13%

Debt/Equity

0.0018

Price to Cash Flow

17.61

Interest Cover Ratio

84.579

CFO/PAT (5 Yr. Avg.)

0.91741010383651

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 49.78 0.00
Mar 2025 49.78 0.00
Dec 2024 49.78 0.00
Sep 2024 49.78 0.00
Jun 2024 49.78 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 0.9304 Cr.
  • Company has been maintaining healthy ROCE of 22.8779063538451% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 84.579.
  • Company’s PEG ratio is 0.460789034176783.
  • The company has an efficient Cash Conversion Cycle of 24.2206 days.
  • Company has a healthy liquidity position with current ratio of 4.0222.

 Limitations

  • The company has shown a poor revenue growth of 11.138324899253% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 147.28 161.21 146.55 168.18 154.07
Total Expenditure 124.55 132.83 122.89 141.46 130.26
Operating Profit 22.73 28.38 23.66 26.72 23.81
Other Income 10.41 9.98 8.97 -6.88 15.27
Interest 0.44 0.35 0.73 0.37 0.21
Depreciation 3.22 3.22 3.22 3.23 3.48
Exceptional Items 0 0 0 0 0
Profit Before Tax 29.48 34.78 28.68 16.25 35.39
Tax 5.81 8.45 7.91 4.67 7.71
Profit After Tax 23.67 26.33 20.77 11.57 27.68
Adjusted EPS (Rs) 11.82 13.15 10.37 5.78 13.82

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 376.09 422.91 472.08 510.31 580.55
Total Expenditure 316.72 335.87 376.61 421.14 480.64
Operating Profit 59.37 87.04 95.47 89.17 99.91
Other Income 12.13 5.74 10 22.48 34.42
Interest 1.98 1.55 1.45 2.03 1.46
Depreciation 5.47 7.56 8.09 9.17 10.62
Exceptional Items 0 0 0 0 0
Profit Before Tax 64.05 83.67 95.93 100.46 122.24
Tax 14.48 21.42 26.57 27.56 28.94
Net Profit 49.56 62.25 69.35 72.9 93.3
Adjusted EPS (Rs.) 24.78 31.08 34.63 36.4 46.58

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 20 20.03 20.03 20.03 20.03
Total Reserves 284.49 346.36 412.85 482.44 572.81
Borrowings 0.52 0.14 0 0 0
Other N/C liabilities 37.47 40.73 41.74 38.02 15.18
Current liabilities 69.44 93.45 110.46 95.85 117.27
Total Liabilities 411.92 500.72 585.08 636.34 725.28
Assets
Net Block 91.03 110.64 131.88 150.53 179.33
Capital WIP 0.04 1.69 16.05 6.71 3.48
Intangible WIP 0 0 0 0 0
Investments 25.79 0.05 0.05 0.05 0.05
Loans & Advances 65.69 61.57 62.57 88.18 70.74
Other N/C Assets 0.03 0.45 1.75 0 0
Current Assets 229.35 326.31 372.78 390.87 471.68
Total Assets 411.92 500.72 585.08 636.34 725.28
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 64.05 83.67 95.93 100.46 122.24
Adjustment 5.38 4.75 1.49 -0.29 -16.76
Changes in Assets & Liabilities 15.27 0.42 2.4 -31.4 -16.12
Tax Paid -13.98 -19.45 -23.64 -29.61 -26.13
Operating Cash Flow 70.71 69.39 76.18 39.16 63.24
Investing Cash Flow -28.99 -64.39 -78.08 -36.64 -57.34
Financing Cash Flow -38.1 -5.74 -2.56 -4.5 -5.18
Net Cash Flow 3.61 -0.74 -4.46 -1.99 0.73

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 49.78 49.78 49.78 49.78 49.78
aashish rajanibhai patel 10.60 10.60 10.60 10.60 10.60
anand arvinbhai patel 1.66 1.66 1.66 1.66 1.66
arvindbhai gulabdas patel... 0.55 0.55 0.55 0.55 0.55
bhagirathbhai tribhovanda... 0.12 0.12 0.12 0.12 0.12
dharmistaben hasmukhbhai ... 0.32 0.32 0.32 0.32 0.32
dharmisthaben bhagirath p... 0.62 0.62 0.62 0.62 0.62
downtown finance pvt. ltd... 0.53 0.53 0.53 0.53 0.53
downtown travels llp 2.37 2.37 2.37 2.37 2.37
hansaben arvindbhai patel... 0.88 0.88 0.88 0.88 0.88
hashmukhbhai ishwarlal pa... 1.87 1.87 - - 1.87
jigar hasmukhbhai patel 0.43 0.43 0.43 0.43 0.43
kailashben mahendrabhai p... 2.40 2.40 2.40 2.40 2.40
mahendrabhai gulabdas pat... 3.37 3.37 3.37 3.37 3.37
mansi munjal patel 1.00 1.00 1.00 1.00 1.00
mihir viththalbhai patel 0.41 0.41 0.41 0.41 0.41
munjal mahendrabhai patel... 13.37 13.37 13.37 13.37 13.37
nidhi mahendrabhai patel 0.27 0.27 0.27 0.27 0.27
patel aniruddh h 0.43 0.43 0.43 0.43 0.43
patel nishitkumar maheshb... 0.77 0.77 0.77 0.77 0.77
rajanikant gulabdas patel... 3.78 3.78 3.78 3.78 3.78
renukaben maheshbhai pate... 0.49 0.49 0.49 0.49 0.49
shivani ashish patel - 1.03 1.03 1.03 1.03
sunmed corporation llp 2.50 2.50 2.50 2.50 2.50
hashmukhbhai ishwarlal pa... - - - 1.87 -
hasmukhbhai ishwarbhai pa... - - 1.87 - -
shivani b. shah 1.03 - - - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 50.22 50.22 50.22 50.22 50.22
dheeraj kumar lohia 1.32 1.32 1.31 1.30 1.30
investor education and pr... - 0.26 - - 0.28
kishor m. shah 2.39 2.39 2.39 2.39 2.39
llp 0.16 0.23 0.20 0.22 0.13
rimo capital fund lp 1.25 1.33 1.33 1.33 1.33
investor education and pr... 0.26 - 0.28 - -
kamlesh jayantilal patel 1.08 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit ICRA
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY21
Presentation Q2FY25
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY21
Presentation Q3FY20

Company News

Lincoln Pharma Stock Price Analysis and Quick Research Report. Is Lincoln Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Lincoln Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Lincoln Pharma has a PE ratio of 12.898130171256 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Lincoln Pharma has ROA of 13.7049% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Lincoln Pharma has a Current ratio of 4.0222.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Lincoln Pharma has a ROE of 17.0372%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Lincoln Pharma has a Debt to Equity ratio of 0.0018 which means that the company has low proportion of debt in its capital.

  • Sales growth: Lincoln Pharma has reported revenue growth of 13.7644% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Lincoln Pharma for the current financial year is 17.2091066809795%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Lincoln Pharma is Rs 1.8 and the yield is 0.3213%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Lincoln Pharma is Rs 43.1109. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Lincoln Pharma in Ticker for free. Also, one can get the intrinsic value of Lincoln Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Lincoln Pharma FAQs

Q1. What is Lincoln Pharma share price today?
Ans: The current share price of Lincoln Pharma is Rs 556.05.

Q2. What is the market capitalisation of Lincoln Pharma?
Ans: Lincoln Pharma has a market capitalisation of Rs 1113.75302544 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Lincoln Pharma?
Ans: The PE ratio of Lincoln Pharma is 12.898130171256 and the P/B ratio of Lincoln Pharma is 1.59256875712618, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Lincoln Pharma share?
Ans: The 52-week high share price of Lincoln Pharma is Rs 979.5, and the 52-week low share price of Lincoln Pharma is Rs 499.

Q5. Does Lincoln Pharma pay dividends?
Ans: Currently, Lincoln Pharma pays dividends. Dividend yield of Lincoln Pharma is around 0.3213%.

Q6. What are the face value and book value of Lincoln Pharma shares?
Ans: The face value of Lincoln Pharma shares is Rs 10, while the book value per share of Lincoln Pharma is around Rs 349.1529. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Lincoln Pharma?
Ans: Lincoln Pharma has a total debt of Rs 1.0668 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Lincoln Pharma?
Ans: The ROE of Lincoln Pharma is 17.0372% and ROCE of Lincoln Pharma is 22.5251%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Lincoln Pharma a good buy for the long term?
Ans: The Lincoln Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Lincoln Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Lincoln Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Lincoln Pharma’s financials?
Ans: You can review Lincoln Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Lincoln Pharma
X